Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.

Pedro Casado, Ana Rio-Machin, Juho J Miettinen, Findlay Bewicke-Copley, Kevin Rouault-Pierre, Szilvia Krizsan, Alun Parsons, Vinothini Rajeeve, Farideh Miraki-Moud, David C Taussig, Csaba Bödör, John Gribben, Caroline Heckman, Jude Fitzgibbon, Pedro R Cutillas

February 2023 Signal Transduct Target Ther

Synopsis of Social media discussions

The discussions reflect genuine interest and moderate engagement, exemplified by comments like 'Great to work with' and references to new preprints, indicating researchers value the methodological advances and potential for targeted therapies. The tone is analytical yet optimistic, emphasizing the study's relevance to ongoing efforts in AML research.

A
Agreement
 Moderate agreement

Most discussions acknowledge or affirm the significance of the study, especially noting the distinction between the two leukemia groups and their therapeutic implications.

I
Interest
 High level of interest

Participants display high curiosity, highlighting the innovative methodologies like phosphoproteomics and the potential clinical benefits.

E
Engagement
 Moderate level of engagement

Comments include mentions of collaboration and ongoing projects, suggesting a moderate level of active engagement and relevance to ongoing research.

I
Impact
 Moderate level of impact

The discourse hints at recognition that these findings could influence future treatments, but the overall tone suggests a developing understanding rather than immediate paradigm shifts.

Social Mentions

YouTube

1 Videos

Twitter

5 Posts

Metrics

Video Views

26

Total Likes

3

Extended Reach

142,107

Social Features

6

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Distinct Biological Groups in KMT2A Rearranged Acute Myeloid Leukemia

Distinct Biological Groups in KMT2A Rearranged Acute Myeloid Leukemia

This study explores two distinct subgroups of KMT2A rearranged AML, MLLGA and MLLGB, showing different biological traits and drug sensitivities, emphasizing potential for targeted therapies based on phosphoproteomic signatures.

Medicine RTCL TV

July 5, 2023

26 views

  • Europe PMC articles
    @EuropePMC (Twitter)

    New from #CR_UK https://t.co/LvHzAkUTok Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.
    view full post

    March 2, 2023

  • Transcriptomes
    @transcriptomes (Twitter)

    Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged ac... https://t.co/Ereh5S1qY4
    view full post

    February 28, 2023

  • Stigmabase | NORTH
    @StigmabaseN (Twitter)

    TW : Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute...: Samples were collected by the Barts Cancer Institute tissue bank in UK ( n = 56) and the Institute for Molecular Medicine... https://t.co/l7UlKQrLlS https://t.co/tY0vUiL9jc
    view full post

    February 28, 2023

  • Pedro Casado Izquier
    @Pedro_Casado_ (Twitter)

    1st preprint for our Poor Risk AML project. Great to work with @pedro_cutillas and @anariomachin Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes https://t.co/BIYUnuEmwn
    view full post

    November 12, 2022

    3

  • bioRxiv
    @biorxivpreprint (Twitter)

    Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes https://t.co/e1CpPp1wy5 #bioRxiv
    view full post

    November 10, 2022

Abstract Synopsis

  • Certain chromosome abnormalities in acute myeloid leukaemia (AML) are linked to poor patient outcomes, and current targeted therapies have limited effectiveness.
  • Researchers studied 74 AML patients using various molecular profiling techniques, identifying two distinct subgroups of KMT2A rearranged leukaemia known as MLLGA and MLLGB, which show different biological characteristics and drug sensitivities.
  • The study suggests that MLLGA has a unique phosphoproteomics signature and is sensitive to specific treatments, indicating potential for developing targeted therapies for patients with this subtype.